Real‐world experience of novel multiple myeloma treatments in a large, single‐center cohort in Finland

In this single‐center study, we aimed to describe the characteristics, treatment patterns, and outcomes of patients with multiple myeloma (MM) following treatment with bortezomib, carfilzomib, daratumumab, ixazomib, lenalidomide or pomalidomide‐based regimens. Data were collected retrospectively fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Loponen, Heidi, Mehtälä, Juha, Ylisaukko‐oja, Tero, Brück, Oscar, Porkka, Kimmo, Koskenvesa, Perttu, Saukkonen, Kirsi, Lievonen, Juha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Haematologic Malignancy ‐ Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660399/
https://www.ncbi.nlm.nih.gov/pubmed/38024616
http://dx.doi.org/10.1002/jha2.802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660399/
https://www.ncbi.nlm.nih.gov/pubmed/38024616
http://dx.doi.org/10.1002/jha2.802

Ejemplares similares